Lantheus (LNTH) to Release Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Lantheus to post earnings of $1.17 per share and revenue of $367.0310 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Lantheus Price Performance

Lantheus stock opened at $73.42 on Tuesday. The company has a fifty day simple moving average of $67.38 and a 200-day simple moving average of $59.68. The firm has a market capitalization of $4.87 billion, a price-to-earnings ratio of 30.85 and a beta of -0.08. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.29.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of recent analyst reports. Truist Financial raised their price target on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Finally, Mizuho raised their price objective on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently modified their holdings of LNTH. EverSource Wealth Advisors LLC increased its stake in Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares during the last quarter. First Trust Advisors LP grew its holdings in Lantheus by 37.4% during the 2nd quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after buying an additional 19,008 shares during the last quarter. Baird Financial Group Inc. boosted its stake in shares of Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 500 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Lantheus by 88.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 1,591 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new position in Lantheus in the 2nd quarter valued at $36,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.